Article Abstract

PARP inhibitor and platinum agent in triple negative breast cancer: utilizing innovative trial design to bring together something “new” and something “old”

Authors: Priyanka Sharma


Triple negative breast cancer (TNBC) which is defined by the lack of expression of estrogen receptor (ER) and progesterone receptor (PgR), and absence of human epidermal growth factor receptor 2 (HER2) over expression and/or gene amplification accounts for approximately 15–20% of all breast cancers.